Clinical trial
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
NCT00780052 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2002
- Completion date
- August 31, 2011
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hematologic malignancies